ErbB3 (HER3) is a member of the EGF receptor (EGFR) family of receptor tyrosine kinases, which, unlike the other three family members, contains a pseudo kinase in place of a tyrosine kinase domain. In cancer, ErbB3 activation is driven by a ligand-dependent mechanism through the formation of heterodimers with EGFR, ErbB2, or ErbB4 or via a ligand-independent process through heterodimerization with ErbB2 overexpressed in breast tumors or other cancers. Here we describe the crystal structure of the Fab fragment of an antagonistic monoclonal antibody KTN3379, currently in clinical development in human cancer patients, in complex with the ErbB3 extracellular domain. The structure reveals a unique allosteric mechanism for inhibition of ligand-dependent or ligand-independent ErbB3-driven cancers by binding to an epitope that locks ErbB3 in an inactive conformation. Given the similarities in the mechanism of ErbB receptor family activation, these findings could facilitate structure-based design of antibodies that inhibit EGFR and ErbB4 by an allosteric mechanism.
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cancer | surface receptor | cell signaling | therapeutic antibodies | crystal structure T he EGF receptor (EGFR)/ErbB family of receptor tyrosine kinases (RTKs) participates in a multitude of roles during embryonic development and in adult homeostasis. In healthy tissues, ErbB signal transduction is initiated through ligandinduced homo-or heterodimerization of receptor extracellular domains leading to the stimulation of tyrosine kinase activity and autophosphorylation of several tyrosine residues in the cytoplasmic domain followed by recruitment and activation of multiple downstream signaling pathways (1) . In contrast, unregulated ErbB signaling through activating mutations, receptor overexpression, or aberrant autocrine ligand signaling loops can lead to cellular transformation and tumorigenesis (2) . Thus, members of the ErbB receptor family (in particular EGFR and ErbB2) have become well-validated targets for the development of anticancer therapeutics, resulting in a number of Food and Drug Administration-approved and marketed monoclonal antibodies and small-molecule tyrosine kinase inhibitors used for treatment of different cancers (3) .
The activity of ErbB3 (also designated HER3) is normally regulated by the neuregulin (NRG) family of growth factors (4), but, unlike other members of the family, ErbB3 functions as an obligate heterodimer with other ErbB receptors because its cytoplasmic domain contains a pseudo kinase in place of a tyrosine kinase domain (5, 6) . ErbB3 therefore takes part in heterodimer formation through ligand binding, whereas its coreceptor (most often ErbB2) provides enzymatic activity to phosphorylate multiple tyrosine residues located primarily in the ErbB3 C-terminal tail. The role of ErbB3 in cancer has been fully appreciated only within the last decade and has prompted the development of several monoclonal antibodies geared at inhibiting its action in solid tumors. ErbB3 phosphorylation and subsequent signaling have been associated with driving tumor progression in several solid tumor types such as breast, lung, head-and-neck, gastric, and thyroid cancers (7) (8) (9) . Moreover, it was proposed that tumor cells use AKT activation through ErbB3 upregulation as a compensatory mechanism for therapeutic inhibition of EGFR and ErbB2 and for targeted inhibition of the MEK and PI3K pathways (10) .
By analogy with EGFR and ErbB4, ErbB3 is thought to exist in an equilibrium between an autoinhibited (tethered) state, which is stabilized by interdomain contacts between extracellular domains 2 and 4, and an extended conformation in which a dimerization arm in domain 2 is exposed (1, 11, 12) . Ligand binding to ErbB3 cross-links domains 1 and 3 intramolecularly and stabilizes the extended form of ErbB3, inducing conformational changes that foster ErbB3 heterodimerization with ErbB2 or other ligandbound ErbB receptors (13) . In cancer cells, tyrosine phosphorylation of ErbB3 through autocrine or paracrine NRG loops promotes tumor cell growth and survival by robustly stimulating the PI3K/AKT signaling pathway.
Ligand-dependent ErbB3 activation can be inhibited by several therapeutic antibodies that function mostly by directly blocking ligand-receptor interactions, resulting in significant antitumor activity in preclinical models of human cancer (14) (15) (16) . By contrast, the requirement for NRG is bypassed in tumors that highly overexpress ErbB2 (such as in subpopulations of ErbB2-amplified breast, ovarian, gastric, and esophageal cancers) (17, 18) . Through Significance Many cancers are driven by aberrant activation of members of the EGF receptor (EGFR) family including ErbB2 (HER2) and ErbB3 (HER3). EGFR and ErbB3 exist in equilibrium between a tethered, inactive conformation and an extended, active state poised toward formation of homo-or heterodimers with other members of the EGFR family, normally in a ligand-dependent manner. In cancers, these receptors are activated by aberrant ligand stimulation or via a ligand-independent mechanism. Here we describe the crystal structure of the extracellular domain of ErbB3 in complex with a therapeutic antibody, revealing a unique allosteric mechanism for inhibition of cancer cells by locking ErbB3 in the autoinhibited configuration. This mechanism offers new therapeutic opportunities for treating cancers driven by aberrant EGFR, ErbB2, or ErbB3 activation.
mass action, overexpression of ErbB2 can force heterodimerization with ErbB3 in a ligand-independent mechanism to provide survival cues to cancer cells. Importantly, because many ErbB3 antibodies currently in clinical development interfere with ligand binding, their ability to inhibit cancers driven by ligand-independent mechanism will be limited.
Here we report the crystal structure of the extracellular domain of ErbB3 bound to the Fab fragment of KTN3379, a fully human anti-ErbB3 antibody currently in phase 1 clinical development for cancer patients that robustly blocks both liganddependent and ligand-independent modes of ErbB3 signaling in models of human cancer. KTN3379 binds with high affinity to a unique epitope in the boundary between domains 2 and 3 in ErbB3 and prevents a conformational rearrangement to the extended form of the receptor that is required for both liganddependent and ligand-independent ErbB3 activation. Our data uncover a novel allosteric mechanism for ErbB3 inhibition with antitumor activity in distinct cancer settings and further suggest that exploiting a similar epitope in EGFR and ErbB4 could yield potent and novel mono-or bispecific therapeutic antibodies.
Results and Discussion
KTN3379 Binds to ErbB3 with High Affinity and Inhibits Both LigandDependent and Ligand-Independent ErbB3 Signaling. KTN3379 was identified as a strong ErbB3-binding Fab from a phage-library screen, followed by affinity maturation to bind ErbB3 with very high affinity. Upon conversion to a fully human IgG1, the CH2 domain in the heavy chain also was modified to improve serum half-life by increasing its affinity to the neonatal Fc receptor (19) . A key criterion in selecting KTN3379 was its ability to inhibit both NRG-dependent and NRG-independent ErbB3 activation in cell-based assays.
We first analyzed the binding of KTN3379 to T47D breast cancer cells, which express moderate levels of ErbB3 on their cell surface. The experiment presented in Fig. 1A depicts a titration of fluorescently labeled KTN3379 (KTN3379-647), revealing binding to T47D breast cancer cells with an apparent affinity of 98 pM. Similar binding affinity was obtained from surface plasmon resonance (SPR) measurements in which the kinetics and binding of purified soluble ErbB3 extracellular domain (sErbB3) to the Fab fragment of KTN3379 (Fab3379) molecules that were immobilized on a sensor chip surface were analyzed. The SPR experiments revealed a K d of 166 pM and an extremely slow dissociation rate of 1.56 × 10 −4 ·s −1 (Fig. 1B) . As determined by binding experiments using SPR measurements, the similarity in the binding affinities of intact bivalent KTN3379 to cells expressing ErbB3 and of monovalent Fab3379 to cells expressing sErbB3 demonstrate that KTN3379 binding to ErbB3 is driven by strong binding affinity rather than by an avidity effect mediated by KTN3379 bivalency.
We next examined whether the binding of KTN3379 to cells harboring ErbB3 on their surface affects NRG binding to the ErbB3 receptor. Ba/F3 cells expressing ErbB3 were treated with 10 nM KTN3379 or buffer alone for 1 h at 4°C followed by treatment with increasing concentrations of fluorescently labeled NRG (NRG-647) for 2 h at 4°C. The experiment presented in Fig. 1C shows that the high-affinity NRG binding mediated by simultaneous NRG binding to domains 1 and 3 of the extended ectodomain configuration is blocked completely by KTN3379 binding to the ErbB3 receptor expressed on the cell surface of Ba/F3 cells. The experiment presented in Fig. 1D shows that KTN3379 binds primarily to an epitope located in domain 3 of ErbB3. In this experiment, KTN3379 was titrated on ELISA plates coated with sErbB3 or coated with each ErbB3 subdomain produced in Sf9 cells, followed by incubation with HRP-conjugated anti-human antibodies. Indeed, the SPR experiment presented in Fig. 1E shows that purified domain 3 binds to Fab3379 immobilized on a BIAcore sensor chip surface. However, a comparison of the SPR analyses reveals that isolated domain 3 binds to Fab3379 with approximately twofold reduced K d of 377 pM that most likely is caused by a 10-fold accelerated dissociation rate (1.74 × 10
), suggesting that KTN3379 may interact with additional ErbB3 region(s).
We next examined the ability of KTN3379 to affect ErbB3-dependent cellular responses in cancer cells. As shown in Fig. S1 , titration of KTN3379 in MDA-MB-175-vii cells, which contain high levels of activated ErbB3 by virtue of an autocrine NRG loop, inhibits ErbB3 and downstream AKT phosphorylation ( Fig. S1A ) and demonstrates robust antiproliferative activity with IC 50 values in the single-nanomolar range (Fig. S1B ). The same titration in BT-474 cells, which express very high levels of ErbB2 but no measurable NRG, also led to a reduction in ErbB3 tyrosine phosphorylation and phospho-AKT levels ( Fig. S1C ) and antiproliferative activity with IC 50 values in the mid-picomolar range (Fig. S1D) . Similar results were obtained in other cell lines in which constitutive ErbB3 activity is driven through either NRG or high ErbB2 overexpression. Interestingly, the measured KTN3379 IC 50 values in ligand-dependent and ligand-independent models differ by one to two orders of magnitude. In liganddependent models, KTN3379 competes with continuously secreted NRG for ErbB3, yielding IC 50 values in the high picomolar to low nanomolar range. By contrast, the IC 50 values in ligandindependent models are markedly lower (and are similar to its measured affinity), likely reflecting the largely unimpeded binding of KTN3379 to ErbB3. We further evaluated the antitumor activity of KTN3379 in mouse xenograft models of human cancer in which tyrosine phosphorylation of ErbB3 is NRG-dependent (Cal27) or NRGindependent and ErbB2-amplified (NCI-N87). Biweekly dosing of KTN3379 at 20 mg/kg for 4 wk was well tolerated and demonstrated significant single-agent antitumor activity in both the Cal27 and NCI-N87 models (Fig. S1 E and F) . Similar results were observed in other tumor models. Thus, KTN3379 antagonizes ErbB3-dependent tumor growth independent of the manner by which it is activated. The inhibitory potency of KTN3379 can be explained by its high binding affinity for ErbB3.
It is noteworthy that KTN3379 treatment of ErbB2-amplified cancer cells resulted in incomplete inhibition of tyrosine phosphorylation of ErbB3, AKT, and cell proliferation. Similarly, treatments with other antibodies against ErbB3 or anti-ErbB2 (such as trastuzumab or pertuzumab) also yield incomplete inhibition of signaling (20, 21) . ErbB2-mediated signaling in this context could result from the formation of several homo-and heterodimer species nucleated by ErbB2, and therefore treatment with a single antibody alone is insufficient to inhibit signaling fully. Indeed, the combination of KTN3379 with trastuzumab resulted in enhanced activity in ErbB2-amplified cancer models relative to either antibody alone. Therefore, KTN3379 is well suited for clinical use in combination treatment with other tyrosine kinase inhibitors, therapeutic antibodies that target ErbB2 and EGFR, or other targeted agents, such as the V600E BRAF mutation in melanoma, which upon inhibition relapse through feedback reactivation of ErbB3 (22) .
Crystal Structure of sErbB3 in Complex with Fab3379. To understand the mechanism of dual inhibition by KTN3379 at the molecular level, the crystal structure of sErbB3 in complex with Fab3379 was determined at 3.20-Å resolution (Table S1 ). The crystals were grown from 18% PEG 3350, 0.2 M ammonium citrate dibasic, and 0.2 M sodium thiocyanate. The structure was solved by molecular replacement using the structure of autoinhibited conformation of ErbB3 (15) and the structure of a Fab fragment that has a high sequence identity with Fab3379 as search models. The protein complex was crystallized in space group P1 with four complex molecules per asymmetric unit. The fully refined structure revealed that Fab3379 binds to a unique epitope in domains 2 and 3 of sErbB3 and locks the receptor in its autoinhibited state ( Fig. 2A) . Least-square superposition of sErbB3 in our structure with the structure of the previously determined autoinhibited sErbB3 extracellular domain (23) shows an α-carbon rmsd of 1.41 Å, confirming that Fab3379-bound sErbB3 is indeed in its inactive conformation (Fig. S2) .
The structure shows that KTN3379 binds predominantly to an epitope in domain 3 of sErbB3, a finding that is in agreement with binding data to each purified ErbB3 subdomain (Fig. 1 D  and E) . The heavy chain variable domain (V H ) of the antibody binds exclusively to the side of domain 3, and the light chain variable domain (V L ) exploits part of domain 3 and wedges itself into the hinge boundary between domains 2 and 3 (Figs. 2 A and  B and 3A) . The combined sum of all interactions buries a total surface area of 900 Å 2 in sErbB3, where the V H chain contributes 470 Å 2 and the V L chain contributes 430 Å 2 . The nearly equal contributions of V H and V L to the overall binding to sErbB3 can be seen clearly in Fig. 2 B and C. The overall shape complementarity parameter for the sErbB3-Fab3379 complex is 0.65, within the values typically observed for antibody-antigen interfaces (24) .
All the contacts observed between Fab3379 and sErbB3 are mediated by the complementarity-determining regions (CDRs) of the antibody molecule. In some cases, several residues in Fab3379 coordinate binding to a single side chain from sErbB3. Of particular importance is Arg402, which forms a partially buried salt bridge with V H Asp103 as well as cation-π interaction with the indole ring of V L Trp92 (Fig. 2D) and thus likely contributes a substantial amount of binding energy to the overall stability of the complex. In addition, Lys337 forms hydrogen bonds with the backbone carboxyl oxygen of V L Leu31 as well as with the side chains of V L Asn32 and V L Asp94 (Fig. 2D) . Conversely, there also are amino acid residues in Fab3379 that simultaneously contact multiple amino acids in sErbB3. For example, V H Tyr33 forms a hydrogen bond with the backbone oxygen of Gly400 as well as hydrophobic interactions with Gly401, Arg402, Ser431, and Arg432. The amino acid residues that make intermolecular contacts and their interactions are summarized in Fig. S3 .
Fab3379 V L Binding to Domain 2 Locks sErbB3 in an Inactive
Conformation. Inspection of the ErbB3 surface that is occupied by KTN3379 shows that the antibody interacts primarily with domain 3 and that fewer interactions also take place with domain 2 and with the hinge connecting domain 3 ( Fig. 3A and Fig. S3 ). The V L region of Fab3379 makes a set of contacts with domain 2 and the hinge region between domains 2 and 3 that are critical for the inhibitory activity of KTN3379. A set of residues from V L CDR1 effectively complements the curvature of the hinge region by enforcing a diverse set of contacts. In particular, V L Leu26 and Leu31 form hydrophobic and van der Waals interactions with hinge region residues Met291 and Pro309, and the interactions are strengthened further by the aliphatic part of Glu292 in domain 2 as well as Ala311 and the aliphatic part of Lys337 in domain 3 (Fig. 3B) . This complementary interface stabilizes the inactive conformation of ErbB3 by restricting the receptor motions essential for the formation of the ErbB3 extended conformation (Movies S1 and S2). Moreover, these interactions have important kinetic consequences for the stability of the complex. Our SPR studies demonstrate that the affinity with which Fab3379 binds to the isolated domain 3 of ErbB3 is approximately twofold lower than the affinity with which it binds to the entire ErbB3 extracellular domain ( Fig. 1 A and E) . Kinetic analysis of SPR data shows that the association and dissociation rates for isolated domain 3 are increased compared with the rates for the intact extracellular domain, arguing that the contacts between Fab3379 and domain 2 of ErbB3 contribute significantly to both kinetic processes. Notably, the K d for sErbB3 is approximately 10 times slower than that for isolated domain 3, indicating that interactions of Fab3379 with domain 2 enhance the K d mainly by decreasing the dissociation rate. The interactions with domain 2 also cause a decrease in the association rate with sErbB3, suggesting that ErbB3, which exists in equilibrium between different configurations, adopts a more restricted configuration(s) upon antibody binding and that the light chain CDR1 of Fab3379 is critical for the stability of the final complex.
The importance of the domain 2-3 hinge region in ErbB receptor activation has been elucidated previously from crystallographic and solution studies of active and inactive ErbB receptors (13) . The hinge region, which is flanked by two rigid disulfide bridges, imposes an important thermodynamic barrier for the transition between the tethered and extended forms of EGFR. Comparison of the crystal structures of inactive EGFR and of ligand-bound EGFR reveal that although the relationship between domains 3 and 4 remains relatively unchanged, the domain 2-3 hinge region acts as a pivot point upon which the receptor rotates and adopts an active conformation. Thus, a high-affinity antibody that binds to this region, such as KTN3379, would be predicted to inhibit EGFR or ErbB4 activation potently by stabilizing the tethered autoinhibited receptor form.
Allosteric Inhibition of NRG Binding to ErbB3 by KTN3379. One important question arising from our structure is whether KTN3379 blocks NRG binding to ErbB3, because ErbB3 activation in many tumors depends on the formation of an NRG-ErbB3 complex. Most reported therapeutic antibodies against EGFR and ErbB3 function mainly by competing directly with ligand-receptor interactions (15, 16, 25) . Because the structure of NRG in complex with sErbB3 has not been solved yet, the structure of domain 3 of sErbB3 was superimposed on the corresponding structure of soluble ErbB4 extracellular domain (sErbB4) in complex with NRG (26) to demonstrate that the ligand-binding footprint of the two receptors is nearly identical. This result is not surprising, because NRG is a high-affinity ligand for both ErbB3 and ErbB4. This analysis shows that the ligand-binding site, as revealed by overlaying the KTN3379-bound sErbB3 structure with NRG-bound sErbB4, is clearly distinct from the antibody-binding site on domain 3 of sErbB3 (Fig. 4A) .
The crystal structure shows that Fab3379 and NRG bind to separate regions in ErbB3, but KTN3379 potently blocks NRG binding to ErbB3 expressed on the surface of cells. Indeed, preincubation of Ba/F3 cells coexpressing ErbB3 and ErbB2 with 10 nM of KTN3379 fully blocks the binding of NRG-647 to ErbB3 (Fig.  1C) . These data support the notion that high-affinity binding of NRG to ErbB3 requires that both ligand-binding sites in domains 1 and 3 are allowed to come into close proximity, similar to EGF binding to EGFR and NRG binding to ErbB4. Therefore, KTN3379 allosterically blocks NRG binding to ErbB3 by preventing domains 1 and 3 from simultaneously binding the ligand, revealing a mechanism of action that is distinct from that of other ErbB antagonists. SI Discussion contains a brief discussion of a previously published antibody (20) that blocks ErbB3 activation through an alternate allosteric mechanism.
A Structural Explanation for the Dual Mechanism of Action of KTN3379. The key distinguishing feature of KTN3379 is its ability to inhibit the first step in a chain of events that leads to both ligand-dependent and ligand-independent ErbB3 activation. Superimposing the activated forms of soluble EGFR extracellular domain (sEGFR) (27) , sErbB4 (26) , or sErbB2 (28) on domain 3 of Fab3379-bound sErbB3 shows that Fab3379 clashes dramatically with a significant portion of domain 2 ( Fig. 4B and Fig. S4 ). The same clash is predicted to occur with the extended form of ErbB3, based on previous small-angle X-ray scattering studies, which demonstrated that NRG binding to ErbB3 stabilizes the extended form of the receptor, resembling that of EGF-bound sEGFR and sErbB2 (13) . This finding confirms that Fab3379 must restrain any intramolecular domain rearrangements when it is Fig. 2B. (B) Detailed view focusing on the interaction between the Fab3379 V L (gray) and the hinge region between domain 2 (red) and domain 3 (green). CDR1 residues in Fab3379 V L wedge the antibody into the hinge region, preventing the conformational rearrangement required for transition from the autoinhibited configuration of sErbB3 to its extended activated form. Listed residues in Fab3379 V L were modified to strengthen the interaction with domain 2 of ErbB3 further, lowering the off-rate of the reaction (Fig. S5) .
bound to ErbB3, particularly given the extremely slow dissociation rate of the complex. Because both NRG-dependent and NRGindependent ErbB3 signaling require that ErbB3 adopt an extended state to form stable heterodimers, blocking domain rearrangement by KTN3379 would effectively prevent the downstream signaling via both pathways. Recently published molecular dynamics studies (29) predict that an NRG-driven ErbB3/ErbB2 heterodimer would form an asymmetric complex resembling a dimer of a ligand-bound form of Drosophila EGFR (30, 31) , and a symmetric NRG-independent heterodimer can stably exist also, particularly under extremely high local concentrations of ErbB2. KTN3379 tightly blocks the very first step in ErbB3 activation and restricts any downstream molecular events, no matter whether the activating source is NRG or high levels of ErbB2 (Fig. 4C) .
Improvement of Binding Kinetics Through Structure-Based Modification of Fab3379. The crystal structure of this complex provides a template that can be used to improve the binding affinity and potency of KTN3379. Thorough inspection of all interactions and complementarity in the complex interface suggests potential mutations that may further improve the stability of the complex. In particular, the interface between V L CDR1 of Fab3379 and the C terminus of domain 2 in ErbB3 (Fig. 3B ) was subjected to structure-based modifications that may provide new interactions without disrupting previously existing ones. Structure-guided introduction of novel interactions in this interface is expected to reduce the flexibility of the domain 2-3 hinge region further and to lower the dissociation rate, thereby improving the overall affinity. Mutation of Fab3379 V L Ser23 to Arg (S23R) and Ser25 to His (S25H) decreased the complex dissociation rate from 1.1 × 10 , respectively (Fig. S5) . These data further emphasize the importance of domain 2 contacts in mediating complex stability and suggest that structure-guided mutations can be used to develop more potent or versatile variants of KTN3379.
Therapeutic Targeting of Other ErbB Receptors by Exploiting the
Same Mechanism of Action. Our data present the possibility of targeting the domain 2-3 hinge region in other receptors, in particular EGFR and ErbB4, with novel and potent therapeutic antibodies with an activity profile similar to KTN3379. Unlike ErbB2, which exists predominantly in an extended state, activation of EGFR and ErbB4 requires intramolecular motions similar to those described for ErbB3 (13) . Empirical approaches such as phage display can be used to develop antibodies that exploit the same region in EGFR and ErbB4. Overlays of Fab3379-bound sErbB3 with the inactive forms of sEGFR and sErbB4 reveal that the overall architecture of the Fab3379-binding epitope is well conserved in all three family members (Fig. S6) . Thus, using our structure as a platform, structure-based antibody engineering could be used to develop antibodies that may cross-react with other ErbB receptors while maintaining the same mode of action. Fig. S6 shows that Fab3379 can be accommodated quite well into the same region of EGFR, ErbB3, and ErbB4, particularly into the flexible domain 2-3 hinge. Only a few minor clashes, largely arising from V H contacts with domain 3, may obstruct binding of KTN3379 directly. Although KTN3379 does not bind to the rest of the ErbB family, conservative modifications in the V H CDR2 predicted to alleviate clashing with a loop in domain 3 along with interfaceoptimizing mutations may suffice to convert KTN3379 into an EGFR-or ErbB4-inhibitory antibody. These engineered antibodies could provide a significant clinical advantage in oncological indications where several ErbB receptors contribute to promote tumor growth, without the need to create bispecific antibodies with two different Fab arms.
Conclusions
ErbB3 has been recognized as an important player in solid tumor biology. Here we report that the inhibitory ErbB3 antibody KTN3379 blocks both NRG-dependent and -independent mechanisms of activation by binding to a novel epitope. KTN3379 forms a complex with ErbB3 with picomolar monovalent affinity and interferes with the first step of its activation, which is required for both modes of signaling. The antibody also precludes ligandreceptor interactions through an indirect mechanism, by interfering with high-affinity cross-linking of NRG by domains 1 and 3. The high affinity measured for the complex is largely the result of an extremely slow off-rate, a highly desirable property in therapeutic antibodies. The unusual stability of the complex results in large measure from the interaction and stabilization of KTN3379 with domain 2, as demonstrated by the accelerated binding kinetics of (Fig. S4) . (C) Mechanism of ErbB3 inhibition by KTN3379. KTN3379 binds and blocks ErbB3 in the first step of ErbB3 activation to lock the ErbB3 extracellular domain in the tethered configuration (marked with a red arrow). Similar to EGFR and ErbB4, ErbB3 exists in equilibrium between a predominantly autoinhibited form and an extended form. The tethered form of ErbB3 (light blue) is stabilized primarily by contacts between domains 2 and 4. During normal physiological stimulation and in several cancers (Upper), NRG binding induces and stabilizes the formation of a dimerization-competent form of the receptor by binding to domains 1 and 3, enabling heterodimerization with ErbB2 (red), ligand-bound EGFR (light green), or ErbB4. In tumors in which ErbB2 is highly overexpressed (Lower), ErbB3 can be activated in the absence of NRG through forced dimerization with ErbB2. In either scenario, ErbB3 activation strongly elicits proliferative and antiapoptotic signals. The dual mechanism of action of KTN3379 therefore hinges on its ability to prevent ErbB3 from sampling a dimerization-competent conformation.
Fab3379 to domain 3 in isolation. Interestingly, our data suggest that KTN3379 binding to cell-surface ErbB3 is likely to be largely monovalent and not driven by avidity, because the apparent affinity for ErbB3-expressing cells did not increase measurably relative to the monovalent affinity measured by SPR. One potential implication of this finding is that KTN3379 could be well suited as one arm of an antibody that engages multiple targets, because the potential loss of avidity (at least to ErbB3) would not be an issue. We further show that the dissociation rate of Fab3379 can be decreased even further through structure-guided mutations, predicted to forge new contacts with domain 2, indicating that further improvements can be made.
Our structure describes a novel and versatile mode of inhibiting ErbB3, a concept that can be expanded to other ErbB receptors such as EGFR and ErbB4 (but not ErbB2). Although the epitope itself is not fully conserved in these receptors, the architecture of this region and their overall mechanism of activation are well conserved. Therefore it is possible to engineer novel inhibitors using structure-based design that simultaneously target more than one ErbB receptor, either by generating antibodies de novo or by modifying KTN3379 using our structural information. These antibodies would function via the same mechanism of action as KTN3379 and might have favorable dissociation kinetics as described above.
Overall, the improved binding kinetics and versatile mechanisms of action that can be achieved by targeting a critical allosteric site essential for receptor activation can provide an advantage over therapies that compete directly with ligand-receptor interactions.
Materials and Methods
The protein complex was concentrated to 8 mg/mL and screened for crystallization with commercially available kits (Hampton Research) and the mosquito automated liquid handler (TTP Labtech) using a hanging-drop vapor-diffusion method. When the equal volumes of the protein solution and reservoir containing 18% PEG 3350, 0.2 M di-ammonium citrate hexahydrate, and 0.2 M sodium thiocyanate were mixed and equilibrated over the reservoir, crystals with the shape of a thin hexagonal prism grew within 1 wk. The size of crystals increased dramatically when the ratio between the protein solution and the reservoir was changed to 2:1. The crystals were cryoprotected by slow transfer to artificial mother liquor supplemented with 30% PEG 400. The diffraction qualities of the crystals were improved significantly by extensive trials of dehydration (32) . The crystals were dehydrated by stepwise transfer to a mother liquor containing 25% PEG 3350, 0.2 M di-ammonium citrate hexahydrate, and 0.2 M sodium thiocyanate and were equilibrated over the same mother liquor for 5 d before cryoprotection. Cryopreserved crystals then were flash frozen in liquid nitrogen.
A 3.20-Å diffraction native dataset was collected at Advanced Photon Source (Argonne National Laboratory) beamline 24-ID-E and processed with XDS (33). The structure was solved by molecular replacement (PHASER) using tethered conformation of sErbB3 (PDB ID code: 4LEO, chain C) and a structure of Fab that has high sequence identities with Fab3379 (PDB ID code: 3H42, chains H and L). Fab3379 in complex with sErbB3 crystallized in space group P1, with unit-cell parameters of a = 84.378 Å, b = 127.141 Å, c = 138.078 Å, and α = 87.10, β = 85.54, γ = 89.92, containing four complex molecules per asymmetric unit (Table S1 ). Iterative rounds of refinement were done using PHENIX (34) with manual inspection using COOT (35) .
All procedures and protocols for in vivo studies were approved by the Institutional Animal Care and Use Committee of WuXi AppTec. Full details about the experiments describing the properties of KTN3379 and expression and purification procedures for proteins used in the study are provided in SI Materials and Methods.
